Pharma times RSS Feed

Leading the agency side, Havas Life Medicom came out on top with three Gold award wins

177Lu-PSMA-617 is being evaluated for the treatment of metastatic castration-resistant prostate cancer

Approximately 1,000 people will be eligible for the treatment in England

The Phase II clinical trial will include at least 360 adolescents aged 12-16 years old

Partnership aims to develop mRNA-encoded antibody therapeutics

Through Entia’s virtual oncology platform, patients are able to perform their own blood tests

NICE has recommended the treatment for people who have at least two attacks per month

Charity-funded project will aim to develop treatments for the high-grade childhood brain tumour

Researchers discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew

Coalition unites a range of stakeholders across healthcare

New evidence collected through the CDF shapes recommendation

Platform launched in a bid to help life sciences companies address the insights gap

Phase Ib trial is evaluating the potential benefit of low-dose psilocybin as a treatment for SUNHA

Retsevmo, Keytruda and Jyseleca accepted for use by NHS Scotland

Children in this age group will be offered one dose of the Pfizer/BioNTech jab from next week

AZ’s combo treatment reduced the risk of disease progression or death by 28% compared to chemotherapy alone

The awards were presented on Thursday 9 September

Gov has alleged that the company breached its obligations under the agreement

The Galleri test is able to identify the ‘earliest’ signs of cancer in the blood

Xeljanz is the second drug to be recommended as part of NICE’s new approach to the cost comparison fast track appraisal process